No ASX ETF holds Dimerix (DXB) as of 15 Oct 2026. Over the last year it fell 60.4%: on $10,000, −$6038. We explain 5 big moves in that time.
About DXB
- SectorHealth Care
- IndustryPharmaceuticals, Biotechnology & Life Sciences
- Size$132.1m
- Held by0 ETFs
- Big moves5 in 1Y
Each dot is a move we explain. Tap one, or a row of Why it moved, to see what caused it.
Why it moved
- +16.3%2 Jul 2026· Sector Flow
Unclear specific catalyst; Dimerix shares moved on heightened small-cap biotech/sector interest rather than company-specific news.
- +10.5%19 Jun 2026· Contract
Dimerix announced a major Asian licensing deal for DMX-200, worth up to A$481 million, driving shares up.
- +21.2%16 Jun 2026· Contract
Dimerix announced a major Asian licensing deal with Everest Medicines for DMX-200 valued up to A$481 million, driving the stock up over 20%.
- −38.5%28 Apr 2026· Operational
Dimerix's Phase 3 kidney disease drug trial (ACTION3) progress update was interpreted as a 'de-risking' move, likely disappointing investors who expected more definitive efficacy data, triggering a sharp sell-off.
- −14.4%24 Dec 2025· Sector Flow
Shares fell despite positive news about Dimerix's US licensing agreement and BioMarin's acquisition of Amicus, likely due to profit-taking or concerns over deal implications.
Held by 0 ETFs
No ETF we track holds DXB directly.
Other Health Care companies
- SHLSonic Healthcare47 ETFs
- RMDResMed44 ETFs
- CSLCSL Limited42 ETFs
- BDXBcal36 ETFs
- CSXCleanspace36 ETFs
- REGRegis Health33 ETFs
- TLXTelix Pharma32 ETFs
- SIGSigma Healthcare31 ETFs
Why did DXB rise 41.7% on 1 May 2025?
Dimerix
Dimerix announced a $940m exclusive US licensing deal with Amicus Therapeutics for its kidney drug DMX-200, sending shares up 41.67%.
The stock surged 41.67% on 2025-05-01, with volume over 10x normal, clearly driven by the announced licensing deal valued at $940m. All three news articles from the same day confirm the agreement, making the cause direct and unambiguous.
Written by a language model from the evidence below, and it can be wrong. Tell us and we will fix or remove it. General information only, not financial product advice. It does not consider your objectives, finances or needs. Past performance is not a guide to future performance.
Evidence
News coverage